Urinary Protein and Peptide Markers in Chronic Kidney Disease

Chebotareva, Natalia; Vinogradov, Andrei D.; McDonnell, Valerie; Zakharova, Natalia V.; Indeykina, Maria I.; Moiseev, Sergey; Nikolaev, Evgeny N.; Кононихин, А. С.

doi:10.3390/ijms222212123

Cited by 20 publications

(16 citation statements)

References 111 publications

(177 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 29 Through the use of a 2D-DIGE-MALDIQ-TOF strategy and related techniques, Patel et al were able to detect novel DKD-related protein biomarkers in at-risk individuals corresponding to the processes of renal tubulointerstitial fibrosis and tubulointerstitial fibrosis, including apolipoprotein A1, α-1microglobulin, and zinc α-2 glycoprotein. 30 , 31 Guo et al discovered that - 1-antitrypsin - 1-acid glycoprotein, ceruloplasmin, prostate stem cell antigen, APOA4 and other apolipoprotein AIV are prospective protein biomarkers of DKD in 23 diabetic patients and 16 healthy volunteers. 32 Liao et al also observed a significant increase in urinary haptoglobin (Hp) levels in DKD patients, allowing for the more accurate diagnosis and prognostic assessment of individuals with this disease.…”

Section: Urinary Protein Biomarkers Of Dkdmentioning

confidence: 99%

Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics

Wei¹,

Han²,

Tu³

2023

DMSO

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) affects an estimated 20–40% of type 2 diabetes patients and is among the most prevalent microvascular complications in this patient population, contributing to high morbidity and mortality rates. Currently, changes in albuminuria status are thought to be a primary indicator of the onset or progression of DKD, yet progressive nephropathy and renal impairment can occur in certain diabetic individuals who exhibit normal urinary albumin levels, emphasizing the lack of sensitivity and specificity associated with the use of albuminuria as a biomarker for detecting diabetic kidney disease and predicting DKD risk. According to the study, a non-invasive method for early detection or prediction of DKD may involve combining proteomic analytical techniques such second generation sequencing, mass spectrometry, two-dimensional gel electrophoresis, and other advanced system biology algorithms. Another category of proteins of relevance may now be provided by renal tissue biomarkers. The establishment of reliable proteomic biomarkers of DKD represents a novel approach to improving the diagnosis, prognostic evaluation, and treatment of affected patients. In the present review, a series of protein biomarkers that have been characterized to date are discussed, offering a theoretical foundation for future efforts to aid patients suffering from this debilitating microvascular complication.

show abstract

Section: Urinary Protein Biomarkers Of Dkdmentioning

confidence: 99%

Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics

Wei¹,

Han²,

Tu³

2023

DMSO

View full text Add to dashboard Cite

show abstract

“…Many hopes to develop innovative diagnostic tools lie in new high-throughput technologies (i.e. ‘omics’) [ 44 ]. Proteomic studies in patients with podocytopathies proposed alpha-1 antitrypsin, transferrin, histatin-3, 39S ribosomal protein L17 and calretinin as new potential urinary markers [ 45 ].…”

Section: Innovations In the Diagnosis Of Podocytopathiesmentioning

confidence: 99%

Defining diagnostic trajectories in patients with podocytopathies

Cirillo

Lugli

Raglianti

et al. 2022

Clinical Kidney Journal

View full text Add to dashboard Cite

Podocytopathies are glomerular disorders in which podocyte injury drives proteinuria and progressive kidney disease. They encompass a broad spectrum of etiologies, resulting in pathological pictures of minimal-changes, focal segmental glomerulosclerosis, diffuse mesangial sclerosis or collapsing glomerulopathy. Despite improvement in classifying podocytopathies as a distinct group of disorders, the histological definition fails to catch the relevant biological heterogeneity underlying each case, manifesting as extensive variability in disease progression and response to therapies. Increasing evidence suggests that podocytopathies can result from a single causative factor or a combination of multiple genetic and/or environmental risk factors with different relative contributions, identifying complex physiopathology mechanisms. Consequently, the diagnosis can still be challenging. In recent years, significant advances in genetic, microscopy and biological techniques revolutionized our understanding of the molecular mechanisms underlying podocytopathies, pushing nephrologists to integrate innovative information with more conventional data obtained from kidney biopsy in the diagnostic workflow. In this review, we will summarize current approaches in the diagnosis of podocytopathies, focusing on strategies aimed at elucidating the etiology standing behind the histological picture. We will provide several examples of an integrative view of traditional concepts and new data in patients with suspected podocytopathies, along with a perspective on how a reclassification could help to improve not only diagnostic pathways and therapeutic strategies, but also the management of disease recurrence after kidney transplantation. In the future, the advantages of precision medicine will probably allow diagnostic trajectories to be increasingly sharpened, maximizing therapeutic results and long-term prognosis.

show abstract

“…In the past decade, urine proteomic mass spectrometry (MS)-based approaches have provided valuable information about protein contents and urinary peptide in CKD with different etiologies [ 110 ]. So far, several disease-specific biomarkers have been identified, such as CD44 in membranous nephropathy, dipeptidase 1 (DPEP1) and apolipoproteins in focal glomerulosclerosis (FSGS), and the laminin G-like 3 (LG3) fragments of endorepellin in IgA nephropathy [ 110 , 111 ]. Although many studies have been carried out in adults, proteomic analysis of CKD has not widespread transferred into the pediatric realm [ 111 , 112 ].…”

Section: Cardiovascular Risks and Biomarkers In Pediatric Ckdmentioning

confidence: 99%

Cardiovascular Risks of Hypertension: Lessons from Children with Chronic Kidney Disease

Tain

Hsu²

2022

Children

View full text Add to dashboard Cite

Hypertension is the most common complication of chronic kidney disease (CKD) in children, having a strong association with subsequential cardiovascular disease (CVD). In pediatric CKD, a considerable percentage of children with hypertension are undiagnosed or undertreated. Prior research has evaluated structural and functional markers of subclinical CVD and biomarkers in adults with CKD, while ideal biomarkers in pediatrics are still insufficiently studied. The ultimate goal of this review is to summarize what is currently known about state of hypertension, cardiovascular risk factors, and potential CVD markers/biomarkers in children with pre-dialysis CKD. We discuss omics-related biomarkers and the pathophysiologic processes of endothelial dysfunction, kidney injury, oxidative stress and inflammation that are classified by specific biomarkers. Moreover, we illustrate the existing challenges and highlight the paucity of pediatric CKD research to evaluate these CVD biomarkers for future clinical pediatric practice. Thus, achieving clinical utility of CVD biomarkers for use in pediatric CKD remains a significant challenge requiring additional efforts.

show abstract

Urinary Protein and Peptide Markers in Chronic Kidney Disease

Cited by 20 publications

References 111 publications

Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics

Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics

Defining diagnostic trajectories in patients with podocytopathies

Cardiovascular Risks of Hypertension: Lessons from Children with Chronic Kidney Disease

Contact Info

Product

Resources

About